Abstract
The Society of Surgical Oncology (SSO) has evolved into the leading academic oncologic society for surgeons. Major contributions by members of the SSO include significant participation in cancer clinical trials and basic biomedical research, which should be maintained and enhanced. Progress with outcomes research for basic, translational, and clinical investigations must be sustained with supportive biomedical technology to complete clinical trials in Phases I–IV. Investment in the development and support of translational researchers is of paramount importance to the future of the discipline.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
